August 31, 2014 4:23 AM ET

Pharmaceuticals

Company Overview of Intra-Cellular Therapies, Inc.

Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate, ITI-007, which is in clinical development for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer’s disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, posttraumatic stress disorder, and intermittent explosive disorder. The company also develops ITI-002 phosphodi...

3960 Broadway

New York, NY 10032

United States

21 Employees

Phone:

212-923-3344

Fax:

212-923-3388

Key Executives for Intra-Cellular Therapies, Inc.

Co-Founder
Age: 61
Total Annual Compensation: $1.1M
Co-founder and Vice President of Business Development
Age: 54
Total Annual Compensation: $283.7K
Chief Financial Officer
Age: 58
Total Annual Compensation: $357.5K
Compensation as of Fiscal Year 2013.

Intra-Cellular Therapies, Inc. Key Developments

Intra-Cellular Therapies, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Intra-Cellular Therapies, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $219,238 against $643,264 a year ago. Loss from operations was $4,611,584 against $8,048,043 a year ago. Net loss was $4,533,539 or $0.15 per share basic and diluted against $8,277,391 or $0.56 per share a year ago. For the six months, the company reported revenues of $387,025 against $1,241,516 a year ago. Loss from operations was $9,186,047 against $13,448,659 a year ago. Net loss was $9,076,823 or $0.33 per share basic and diluted against $13,915,768 or $0.95 per share a year ago.

Intra-Cellular Therapies, Inc., Q2 2014 Earnings Call, Aug 12, 2014

Intra-Cellular Therapies, Inc., Q2 2014 Earnings Call, Aug 12, 2014

Intra-Cellular Therapies, Inc. Appoints Michael Halstead as Senior Vice President and General Counsel

Intra-Cellular Therapies, Inc. announced the appointment of Michael Halstead as Senior Vice President and General Counsel. In this role, Mr. Halstead will manage the legal affairs of the company, and will report directly to Sharon Mates, Ph.D., CEO and Chairman of Intra-Cellular Therapies. Mr. Halstead most recently served as Senior Vice President, Corporate Development at Warner Chilcott plc.

Similar Private Companies By Industry

Company Name Region
Synapsin Pharmaceuticals, Inc. United States
PharmaNutrients, Inc. United States
Biotab Nutraceuticals Inc. United States
Westwood-Squibb Pharmaceuticals, Inc. United States
Adheron Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intra-Cellular Therapies, Inc., please visit www.intracellulartherapies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.